RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Not yet recruiting · NCT07114432 · Registry updated 2025-08-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 | 2025-08-11 | NCT07114432 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Allorunning Therapeutics | 5 |
| Tianjin Medical University Cancer Institute and Hospital | 287 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Cancer Hospital Airport Hospital | Tianjin | China | 6 |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin | China | 66 |